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sWhile surgical aortic valve replacement has been an ex-traordinarily effective treatment for symptomatic aor-
ic stenosis, it has been estimated that over 40% of patients
ith this condition go untreated.1 Many of these face prohib-
tive operative risk, due to a number of factors such as por-
elain aorta, cirrhosis, severe emphysema, and other comor-
idities. Recently, transfemoral transcatheter aortic valve
mplantation (TAVI) has demonstrated clinical benefit in a
atient population at prohibitively high risk for complica-
ions following traditional surgical valve implantation.2
The initial application of this technology in human pa-
tients utilized an antegrade approach via the femoral vein, a
transseptal puncture, and guidance of the prosthesis across
the mitral valve and out through the left ventricular outflow
tract.3 Although this approach avoids the complications as-
sociated with large-bore access of the iliofemoral arterial sys-
tem, it proved cumbersome for most operators and was as-
sociated with a high risk of other major complications,
including cardiac perforation andmajor structural damage to
the mitral valve.
In recent years, TAVI procedures with a balloon-expand-
able system have been performed retrograde either through a
transfemoral arterial approach (TF) or through a transapical
approach involving a limited left thoracotomy and exposure
of the apex of the heart. For the purposes of this article, we
focus on the TF technique using the Edwards Sapien balloon-
expandable platform (Fig. 1; Edwards Lifesciences, Irvine,
CA). This device is not currently approved for marketing in
the United States and is limited to investigational use; it is
currently the only device in clinical trial in the United States,
although it has been Conformite European (CE) mark ap-
proved for use in Europe since September 2007. Another
transcatheter aortic valve device, the Medtronic Corevalve
(Medtronic, Inc, Minneapolis, MN), has impending clinical
trials in the United States and has also received CE mark
approval. A number of other innovative transcatheter valve
devices are in various stages of preclinical and clinical testing
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The preoperative steps of this procedure, other than
general patient selection, include proper evaluation of il-
iofemoral and aortic access for retrograde device deploy-
ment and accurate annulus sizing. The critical procedural
steps include the following: reassessment of annular size,
vascular access, accurate valve positioning, reliable rapid
ventricular pacing, valve deployment, valve assessment,
and control of vascular access and closure. The procedural
steps of retrograde valve positioning and deployment have
been well described4 and we focus much of this discussion
n our technique for total percutaneous device placement.
hese techniques can also prove useful for other large-
ore arterial access systems, such as endovascular aortic
tent-graft placement.
Patient Screening
The worldwide experience with TF-TAVI reveals that vascu-
lar access complications are both common and associated
with significantly increased risks of morbidity and mortality.
Therefore, all potential patients enrolled for TAVI undergo
imaging of their aorta and iliofemoral systems. Generally this
involves both invasive angiography and 3-dimensional com-
puterized tomography (3D-CT). Ideally the 3D-CT uses IV
contrast but, in some circumstances of impaired renal func-
tion, images obtained with low or no contrast administration
may be used to complement the invasive angiography. In
patients with impaired renal function, we use a combination
of noncontrast CT and intravascular ultrasound to evaluate
vessel size, calcification, and diameter.
Vessels are evaluated for cross-sectional diameter, calcifi-
cation, plaque or thrombus, and tortuosity. The current iter-
ation of the Edwards Sapien device is available in 2 sizes: 23
mm and 26 mm. At the current time, the sheath required for
placement of a 23-mm Sapien valve is 22 French (25 French
outer diameter, 8.5 mm), whereas the sheath required for the
26-mm valve is 24 French (28 French outer diameter, 9.3
mm). The minimal acceptable vessel diameter for the 23 mm
valve is 7 mm and for the 26-mm valve is 8 mm. In the
presence of marked tortuosity or calcification, we generally
prefer even larger diameter vessels. Careful screening can
valsalv
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an oversized sheath.
Although we have favored a percutaneous approach to fem-
oral access, a number of situations favor surgical exposure of the
common femoral artery. First, the extremes of patient size may
complicate a percutaneous vessel closure. Obese patients have a
higher reported incidence of complications from percutaneous
vessel closure, although they also stand to gain the greatest ben-
efit from percutaneous closure to avoid wound complications.
Patients with a paucity of subcutaneous tissue may have mini-
mal distancebetween the skin and the artery andbepredisposed
to infection of the closure device sutures. Moreover, these pa-
tients can have a very limited incision for open vessel exposure.
Other groups in whom we have utilized surgical exposure are
those with synthetic femoral arterial conduit or extensive vessel
calcification and those with significant scar tissue. These situa-
tions may prevent proper deployment of the closure device su-
tures. Despite these limitations, we have been able to utilize a
truly percutaneous access in the majority of our TF-TAVI pa-
Figure 1 Post-deployment view of Sapien THV (transca
native aortic valve leaflets displaced into the sinuses oftients.Patient
Preparation and Valve Sizing
Accurate sizing of the aortic annulus is critical to procedural
success. The 23-mmSapien valve is intended for use in native
aortic annulus ranging from 18 to 21 mm, whereas the
26-mm valve is used in annulus sizes 22 to 25 mm. Some
degree of oversizing is desirable, to gain a secure purchase of
the valve stent on the native aortic valve tissue and to mini-
mize risk of significant perivalvar leak. Choosing a grossly
oversized valve can result in incomplete expansion and sec-
ondary prosthetic leaflet dysfunction as well as increase the
risk of coronary ostial occlusion and aortic dissection. Con-
versely, an undersized valve can cause perivalvar leak and, in
more extreme cases, lead to valve dislodgment. In the pub-
lished clinical experience as well as the postmarket registry
data for countries that have granted device approval, there
have been no documented cases of late valve dislodgment or
embolization when sized according to protocol.
eart valve) in position at the native annulus, with the
a. a.  artery; THV  transcatheter heart valve.theter hThe principal technique for annulus sizing has been echo-
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32 M.J. Davidson, F.G.P. Welt, and A.C. Eisenhauercardiography. Typically, a parasternal long-axis view will
give the most reliable annulus sizing. This view also can give
information about excessive mitral annular or anterior leaflet
calcification or upper septal hypertrophy, both of which can
adversely affect proper valve deployment. We have found
several techniques to be quite helpful in accurate annulus
sizing. First, we feel it is critical for the physician implanting
the valve to personally review the echocardiogram and CT
rather than relying on the reports, as they will have the best
understanding of the actual landing zone for the valve. Sec-
ond, we and others have noted that the annulus measure-
ment by transthoracic echocardiogram often underestimates
true annulus size and have found transesophageal echocar-
diogram (TEE) to yield larger, and generally more accurate,
annulus size measurements. In addition, given that all pa-
tients undergo a screening CT scan, the 3-dimensional recon-
structions allow one to obtain a third annulus measurement.
We have found that this correlates more closely with TEE
rather than transthoracic echocardiogram values, although
this is unproven. The TEE that is performed in nearly all
TAVI patients at the time of the procedure allows a final
annulus measurement before committing to a prosthetic
valve size.
Procedural Steps
This procedure may be performed in a hybrid operating
room with a high-quality fixed fluoroscopy system or in a
catheterization laboratory that is appropriately designed for
sterile surgical procedures. The patient is positioned supine
on the procedural table, where anesthesia is induced. We
have found that the role of the anesthesiologists in these
procedures has not been extensively discussed in the litera-
ture but is of the utmost importance to procedural success.
Many sites, such as ours, utilize a dedicated group of cardiac
anesthesiologists highly trained in TEE and are an integral
part of the TAVI team. In addition to monitoring and main-
aining proper hemodynamic stability, the anesthesiolo-
ists can continuously assess and relay TEE information.
n addition, having a dedicated anesthesia team allows
onsistent and efficient communication regarding changes
n the patient’s clinical status. Some sites have utilized
onscious sedation without endotracheal anesthesia to
erform these procedures. The majority of centers, includ-
ng ours, have chosen to use general endotracheal anesthe-
ia during TAVI. In addition to patient comfort and airway
ontrol, this technique minimizes the risk of patient move-
ent during critical portions of the procedure. After
lacement of appropriate monitoring lines including arte-
ial line and pulmonary artery catheter, the process of
emoral arterial access begins.
Vascular Access
It is important to choose the site of the large-bore access
sheath carefully. One should make a preliminary choice
based on the findings at cardiac catheterization and iliac an-
giography—and based on CT angiography—both of which
will have been done before the TAVI procedure. Special at-
tention should be paid not only to the minimum diameter of
the iliac and common femoral vessels but also to the locationof fluoroscopic calcium and, in particular, anterior calcified
plaque right at the puncture site, which will make percuta-
neous closure more difficult and, in some instances, prompt
the use of surgical cut-down rather than a percutaneous ap-
proach. Similarly, the most common site of access misadven-
ture is in the external iliac artery commonly at the junction of
the external and common iliacs; this site should be carefully
scrutinized.
Once the potential site is chosen and the patient is suit-
ably prepared, we characteristically use a Cook mi-
cropuncture set (Cook, Bloomington, IN) to obtain vascu-
lar access. Despite the use of general anesthesia, we
infiltrate local anesthetic in hope of maintaining patient
comfort following the emergence from general anesthesia.
The potential insertion site is imaged fluoroscopically and
marked with a metallic object (usually a hemostat). We
plan to access the artery at the midpoint of the femoral
head, in the common femoral artery, caudal to the inguinal
ligament and proximal to the bifurcation to the superficial
femoral (SFA) and profunda arteries (Fig. 2A). An anterior
wall puncture is made and the 0.018-inch guidewire sup-
plied in the kit is inserted under fluoroscopic guidance.
We then insert only the inner dilator from the micropunc-
ture sheath, which is about the same diameter as the 21-
gauge access needle. Through this we make a local angio-
gram to confirm the site of arterial puncture and its
relationship to the inguinal ligament and to the distal fem-
oral bifurcation (Fig. 2B). If this site proves acceptable, the
inner dilator is removed, and the guidewire remains in
place. The inner dilator is re-mated with the micropunc-
ture sheath, and this is placed in the vessel over the wire.
The wire and inner dilator are removed and a 0.035-inch
guidewire is passed through this sheath. Over this guide-
wire, we place an 8-French sidearm sheath. If it is thought
necessary, a second angiogram can be made through this
sheath to reconfirm appropriate position. Obtaining ac-
cess in the optimal spot is key to a successful percutaneous
approach.
At this point we enlarge the dermatotomy down to the
artery so that it will receive the barrel of a 10-French Prostar
closure device (Abbott Laboratories, Abbott Park, IL). Some
operators prefer to use two 6-French PerClose Proglide de-
vices (Abbott Laboratories) that are inserted at differing an-
gles. Of note, the “preclose” method with either device for
large-bore access is an off-label usage. We continue to prefer
the ProStar because its sutures are not preknotted, affording
more precise control. When using the ProStar device, it is
critical to create an adequate dermatotomy and subcutaneous
tunnel (Fig. 3A). In addition, the device must be properly
placed in the artery at approximately a 45-degree angle to
ensure proper suture needle deployment (Fig. 3B). Once de-
ployed, the sutures are secured with 2 hemostats, moistened,
and maintained under moist gauze off to 1 side of the punc-
ture. Finally, we replace the guidewire and place a 10- or
12-French sheath in the artery.
At this point, access is obtained in the contralateral
groin, in the common femoral artery, and vein. We gener-
ally place a 6-French sheath in each. An OmiFlush cathe-
ter is advanced to the abdominal aorta just superior to the
bifurcation. The contralateral common iliac is instru-
mented with a 0.035-inch Terumo Glidewire, which is
Percutaneous balloon-expandable aortic valve implantation 33manipulated distally into the common and external iliac
arteries past the indwelling 10-French sheath and into the
SFA. If possible, the Omni flush catheter is advanced over
the guidewire and into the contralateral SFA. At this point,
we replace the glide wire with a moderately supportive
0.035-inch wire such as a Rosen wire over which we pass
a 7-French Balkan sheath as far distal as possible (Fig. 4A).
We replace the 0.35-inch guidewire with an 0.018-inch
Steelcore wire and withdraw the Balkan sheath just distal
to the aortic bifurcation. This allows us to maintain access
to the entire iliofemoral system on the side of large-bore
access and permits the contralateral advancement of a 5-
or 6-French pigtail catheter to the ascending aorta (Fig.
4B). We believe that creating wire access to the SFA from
Figure 2 Localizing the optimal site for femoral arteria
ligament. Note location of arterial puncture at common f
inguinal ligament. (B) Femoral angiogram through a mi
access site. a.  artery; lig.  ligament.the contralateral side at the beginning of the procedureprovides the greatest safety and flexibility during large-
bore access sheath removal.
Next we advance an Amplatz extra stiff wire through the
10-French sheath followed by a serial dilatations. We be-
lieve that slow stepwise dilatations are preferable and thus
we remove the 10-French sheath and dilate the access site
with 12- and 14-French dilators before beginning dilata-
tions with the 16-French dilator in the Edwards intro-
ducer set. This process is best performed by 2 operators—
the person closest to the access site will advance the
dilators, while an assistant standing to his right will secure
the wire. Advancement of the larger sizes is done slowly
with a to-and-fro rotation. Following advancement, with-
drawal can be accomplished by the assistant who will
s. (A) Anatomy of the femoral vessels at the inguinal
artery, above the bifurcation of the artery and below the
cture dilator demonstrating appropriate femoral arteryl acces
emoral
cropunwithdraw the dilator slowly using an opposite motion
34 M.J. Davidson, F.G.P. Welt, and A.C. EisenhauerFigure 3 Use of the 10 French Perclose Prostar (Abbott Laboratories, Abbott Park, IL) used to “preclose” the access in
the femoral artery. (A) Demonstrates the device in the artery, with (B) showing the sutures after deployment. Note that
use of this device for preclosure of large-bore access is off-label in the United States. a.  artery.
Percutaneous balloon-expandable aortic valve implantation 35Figure 4 Strategy for managing femoral access percutaneously. (A) A sheath crossing over from the left common femoral
artery to the left iliofemoral system. (B) The sheath pulled back to the descending aorta with its 0.018-inch guidewire
maintained in the contralateral femoral artery and a 0.035-inch guidewire going to the aortic arch, over which a pigtail
catheter will be placed. (C) The Sapien delivery sheath placed from the left common femoral artery, alongside the
previously placed 0.018-inch guidewire. (D) The Sapien delivery sheath being pulled back, with the contralateral
sheath used to deliver a proximal compliant balloon to the iliac artery above the sheath.
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will take care to maintain hemostasis by direct pressure
once the sheath is removed. This is repeatedly performed
serially with all the dilators advanced under careful fluo-
roscopic visualization. In many instances, it is possible to
observe arterial calcifications fluoroscopically and, by
considering their movements, understand how the iliac
artery system is being stressed or deformed. The more
resistance is felt, the more the advancement should be
slow and deliberate. Occasionally it may not be possible to
advance the largest dilator and this is a point at which the
prudent operator may wish to abandon this approach and
consider an alternate means of access such as an iliac con-
duit.
Once the largest dilator has been passed and removed, the
previously prepared access sheath is placed in an identical
fashion. It is important to watch every aspect of this advance-
ment under fluoroscopy and advance the radiopaque tip of
this sheath into the abdominal aorta. When the sheath is in
place, the dilator can be removed and the sheath flushed
when access has been obtained. At this point, there is the
large-bore sheath on the access side and next to a 0.018-inch
Steelcore wire that passes from the contralateral iliac system
alongside of the sheath and ends distantly in the superficial
femoral artery (Fig. 4C).
If it has not been done beforehand, access for a pacing
catheter should be obtained in the femoral vein on the side
opposite of the large-bore access. Of note is that we prefer a
temporary screw-in lead for these cases. Once this lead is
placed successfully, it is difficult to dislodge as opposed to a
standard temporary bipolar pacing catheter, which can easily
be moved. The loss of rapid ventricular pacing even for 1 or
2 beats during valve deployment can result in disastrous
ejection of the valve cranially into the ascending aorta; we
find that this pacing catheter offers the greatest stability. Pac-
ing thresholds are tested and the wire position adjusted as
necessary to achieve a reliable pacing capture. Once vascular
access is secure, the patient is fully heparinized. We begin
with 70 units per kilogram of unfractionated heparin and
monitor activated clotting time closely to maintain it above
250 seconds.
A 5-French or 6-French angled pigtail angiographic cath-
eter is advanced to the aortic root from the Balkan femoral
sheath and used to determine the ideal fluoroscopic angle for
showing the aortic annulus in a planar fashion. This is im-
portant for determining appropriate location for valve de-
ployment. The calcium landmarks on the native valve can be
misleading and it is important to correlate these with the true
aortic annulus determined by aortic root angiography. Typ-
ically, we have found a nearly AP-to-AP-caudal angulation of
the fluoroscopy gantry yields a planar view. Depending on
the patient’s anatomy, a left anterior oblique-cranial or right
anterior oblique-caudal angle may be optimal. This may
sometimes be predicted by preprocedural catheterization or
CT angiography studies and newer software programs may
allow more accurate prediction of ideal angulation. This can
reduce the need for repeated root angiograms and resultant
contrast load.
Balloon Dilation
Once all vascular access is obtained, the stenotic valve is
crossed and a catheter is placed in the left ventricle. Gen-erally we prefer a 6-French pigtail catheter and a 0.035-
inch straight wire for crossing the valve. There are how-
ever many ways in which this can be accomplished and
many operators prefer an Amplatz curve or a right Judkins
catheter. Nevertheless, once the valve is crossed, and the
pigtail or other catheter is advanced, a transaortic gradient
is measured along with the appropriate hemodynamics
from indwelling pulmonary artery line. The left ventricu-
lar catheter that was advanced from the large-bore access
is removed over an exchange-length Amplatz short tip
extra stiff wire that has been precurved to sit in the apex of
the left ventricle with a minimum of ectopy. This curve
also minimizes the risk of apical perforation.
Although the initial balloon aortic valvuloplasty (BAV)
may be performed with a smaller sheath (usually 10-12
French), we have opted for a practice of placing the valve
delivery sheath before crossing the valve and performing
BAV. The disadvantages of this approach are that the large
sheath has been placed (thus exposing the patient to the
peripheral vascular complication risk) before crossing the
native aortic valve and performing the dilation. Theoretically,
a patient could have a native valve that cannot be crossed or
dilated and therefore not receive the prosthetic transcatheter
valve. This scenario, however, is quite uncommon, occurring
in less than 2% of registry patients. Second, keeping the
large-bore sheath, with its hydrophilic coating, for a longer
period of time in the artery can predispose the sheath to
become more adherent and difficult to remove. Given the
short time taken to cross and dilate the valve, however, we
have not felt this added time to be significant.We feel that the
advantages of early sheath placement to be significant. These
include the ability to rapidly place the Sapien valve should
the patient become hemodynamically unstable secondary to
BAV. This may happen if significant aortic insufficiency is
created by the BAV. Also, we minimize the risk of losing wire
access to the left ventricle in the process of exchanging the
smaller sheath for the delivery sheath. This becomes more
important in the infrequent instance of discovering the need
for surgical retroperitoneal exposure and direct iliac cannu-
lation or conduit placement. Last, complete inability to safely
place the sheath, while again infrequent, allows one to devise
an alternative treatment strategy, such as high-risk surgical
aortic valve replacement (AVR) and possible future transapi-
cal TAVI, before subjecting the patient to the risk of BAV.
Given the presence of a large-bore access, a wide variety
of balloon dilation catheters can be chosen without regard
to sheath size. We tend to use Tyshak or Z-med II catheters
with diameters just slightly smaller than the echocardio-
graphically measured annulus size. In general a 22-mm
balloon is the most common size that is selected. Careful
balloon preparation reduces the likelihood of air embo-
lism in case of balloon rupture. A mixture of contrast to
saline of 1:4 allows fluoroscopic visualization and rapid
balloon inflation and deflation. The purpose of the BAV is
to assure that the native valve is amenable to TAVI and to
allow the device to cross the previously stenotic valve.
Additionally, simultaneous injection of contrast into the
aortic root during BAV can allow final confirmation of
appropriate prosthetic valve sizing and adequate clearance
between the native leaflets and coronary ostia. Finally, this
is when we first test rapid ventricular pacing to find an
Percutaneous balloon-expandable aortic valve implantation 37appropriate rate to eliminate cardiac output. Typically,
this is between 180 and 210 bpm and needs to reduce the
pulse pressure maximally (generally to below 40 mm Hg)
to avoid ejection of the balloon. Excessive rapid pacing
runs may adversely impact ventricular function and there-
fore should be confined to BAV and device delivery once
an appropriate pacing rate has been established.
Taking care to watch the aortic pressure carefully, the bal-
loon is advanced across the valve, rapid pacing is initiated,
and a rapid inflation is performed (Fig. 5A). One or more
dilatations can be performed—the concept is to provide pre-
dilatation so that the valve can be advanced and not to pro-
vide a definitive valvuloplasty result. In addition, once the
balloon valvuloplasty is performed, it is possible that severe
aortic regurgitation could supervene and one must be pre-
pared to place the aortic valve very promptly once balloon
dilation is initiated. Not only does this process allow one to
predilate the valve to ensure relatively easy passage of the
valve and balloon delivery catheter but also allows additional
assessment of annulus size and will help demonstrate how
rapid ventricular pacing will be tolerated and whether or not
the patient has a quick or prolonged hemodynamic recovery.
Once predilatation is judged adequate, the balloon catheter is
removed and the valve assembly can be advanced into place.
Valve Placement and Deployment
It has been our practice to mount the prosthetic valve
before BAV, in the event of sudden hemodynamic insta-
bility requiring rapid valve deployment. The steps for
mounting the valve on the delivery catheter are protocol-
driven and have been well-described. They have evolved
somewhat as the delivery catheters have iteratively
changed. Currently, with the RetroFlex-3 catheter, the
balloon is filled with a 1:4 contrast mixture and calibrated
to the appropriate size. Meticulous de-airing is performed,
along with flushing of the wire channel. The flexing mech-
anism is tested. The valve is then crimped onto the deliv-
ery balloon using a specially designed crimping device.
This is done shortly before the anticipated device deploy-
ment to minimize time that the valve is in a crimped state,
with its theoretical damage to leaflets. The mounted device
and balloon are resized to ensure that they will traverse the
sheath and then placed into a loader. The operator assures
that the valve is mounted in the correct orientation. The
device is now ready for use.
The valvuloplasty balloon is removed and exchanged
for the device delivery catheter. Importantly, once the
valve is advanced out of the tip of the sheath into the aorta,
it cannot reliably be withdrawn back into the sheath.
Therefore, it is critical to assure that the valve is correctly
mounted and that the wire position in the left ventricle is
maintained. As the catheter tip approaches the aortic arch,
the flexing mechanism is maximally engaged to allow the
catheter to traverse the arch with minimal trauma (Fig.
5B). The native valve is crossed; care must be taken at this
juncture to avoid pushing the catheter too far into the left
ventricle and risking perforation. The valve is positioned
in the native annulus using a combination of calcium land-
marks and root angiography (Fig. 5C). This process may
need to be expedited if the patient suffers hemodynamicinstability secondary to obstruction of the aortic outflow.
However, one must be confident of optimal valve position
before deployment and occasionally it may be appropriate
to withdraw the valve to the ascending aorta if necessary to
regain hemodynamic stability while assessing proper po-
sition. With the RetroFlex-3 catheter, the valve is best
positioned with the midpoint of the valve at the radio-
graphic aortic annulus. We perform additional confirma-
tion by TEE before deployment. Respirations are sus-
pended to minimize movement; rapid pacing is initiated,
and the deployment balloon is inflated maximally (Fig.
5D). Generally, the inflation is held for several seconds to
allow proper valve expansion. Rapid pacing is maintained
until the balloon is fully deflated. Given the prolonged
period of rapid pacing, patients may at this point experi-
ence a period of hemodynamic instability. The team must
be prepared for expeditious defibrillation and for hemo-
dynamic support—generally pharmacologic.
A rapid TEE assessment is performed to assure proper
valve position and function and to assess for perivalvar leak.
The presence of a significant perivalvar leak may prompt a
balloon re-inflation to attain better seal against the native
annulus. If this is performed, it must be again donewith rapid
pacing and care must be taken not to oversize the stent or
“flare” the distal end of the stent, which could cause leaflet
malcoaptation leading to central aortic regurgitation. In the
rare instance of leaflet dysfunction, another valve may be
deployed within the first (“valve-in-valve”) for salvage. In
cases of central aortic insufficiency, the culprit may be defor-
mation of the prosthetic leaflets by the Amplatz wire. We
prefer to remove this for formal echocardiographic evalua-
tion after a rapid assessment of basic valve function and peri-
valvar leak (Fig. 5E). After echocardiographic assessment,
gradients are measured and a complete aortogram performed
to further demonstrate valve function.
Access Removal and Hemostasis
Following acceptable placement of the aortic valve prosthe-
sis, the next serious hurdle is successful removal of the large-
bore arterial access and the avoidance of complications.
At this point the team should be aware that if it was
difficult to advance the large-bore sheath, removal will
likely be difficult. First, the outside diameter of the sheath
may be approximately equal to, or even slightly greater
than, the inside diameter of the artery. Second, the sheath
has been in place for a significant time and blood has been
excluded from the space between the sheath and the ar-
tery, in effect “drying out” the sheath and defeating the
lubricious coating of it. Thus removal can be problematic.
Although it is possible to perforate the aorta or the iliac
arteries on sheath advancement, the most common source
of hemorrhagic complication is avulsion of the iliac ar-
tery—particularly the external iliac—at the time of sheath
removal. Various techniques familiar to those skilled in
peripheral intervention, such as local infusion of vasodi-
lators through microperfusion catheters, may be useful.
At this point, arterial pressure should be monitored from the
side arm of the large-bore access sheath and from the contralat-
eral Balkan or similar sheath. Most operators replace the large-
boredilator and slowlywithdraw the sheathuntil its end is in the
38 M.J. Davidson, F.G.P. Welt, and A.C. EisenhauerFigure 5 (A) A balloon aortic valvuloplasty performed using retrograde arterial access. (B) The Sapien valve being
maneuvered along the aortic arch over the guidewire toward the aortic valve. (C) The Sapien valve positioned in the
native aortic annulus. (D) Balloon inflation, deploying the prosthetic valve in the native aortic annulus. (E) The Sapien
valve after deployment.
Percutaneous balloon-expandable aortic valve implantation 39common iliac artery. Although not common, uncovering an
aortic perforation can occur at this time. Should hypotension or
hemodynamic compromise ensue, this is an important aspect of
the differential diagnosis that can be confirmed or refutedwith a
local angiogram. Aortic occlusion (Coda) balloons and proto-
cols for their use should be available.
As the large-bore sheath is removed into the common
iliac artery, the contralateral Balkan, Ansell, or Arrow
sheath is advanced over the 0.018 indwelling guidewire
well into the contralateral common iliac. At this point,
contrast injections can be made through this sheath to
document the status of the iliac system on the side of
large-bore access. It is important to note that the sheath
withdrawal actually elongates and narrows the artery in
which the sheath is placed; too rapid a withdrawal or the
application of too much force can avulse the external from
the common iliac artery and lead to an unsalvageable sit-
uation. Thus it is important to monitor this process with
contrast injections and pressure monitoring. A standard
0.035-inch compatible 4-cm-long angioplasty balloon is
used for occlusion and is advanced through the contralat-
eral sheath to the external iliac artery on the side of the
large-bore valve delivery sheath (Fig. 4D). From local an-
giography and from preprocedure imaging, the diameter
of the external iliac should be sufficiently known to pick
an occlusion balloon for the external iliac. Commonly,
balloon sizes range from 7 to 12 mm, depending on the
diameter of this vessel.
At this point, with gentle inflation of the balloon, theFigure 5 (Contdistal pressure as measured from the side arm of the Sa-
pien delivery sheath should diminish to that of the collat-
erals supplying the limb. This is an indication that the
balloon has virtually occluded the vessel and has “depres-
surized” the insertion site. The large-bore access is com-
pletely removed and the indwelling sutures from the 10-
French ProStar are carefully tied. After a short waiting
period, the balloon is deflated while injecting small
amounts of contrast into the Balkan sheath to outline the
puncture site. If there is any extravasation, the balloon can
be advanced across that area and inflated gently to reduce
the pressure on the wound in the vessel. We find this
method is extremely effective in patients whose iliac ves-
sels meet size criteria and have little or no anterior calci-
fication of the vessel at the puncture site. Once hemostasis
is complete, the 0.018-inch wire can be removed and oc-
clusion devices of choice used on the contralateral access
sites.
Postoperative Care
Postprocedure, all patients are monitored in an intensive
care setting for at least 12 to 24 hours. Cardiac rhythm is
continuously monitored and the presence of new ventric-
ular conduction delay or block may prompt prolonged
presence of the temporary pacing wire or even consider-
ation, although infrequent, of permanent pacemaker im-
plantation. As with any traditional AVR patient, careful
fluid and hemodynamic monitoring are standard. In addi-inued)
40 M.J. Davidson, F.G.P. Welt, and A.C. Eisenhauertion, access sites and peripheral perfusion are assessed
frequently. Patients may be mobilized on the day follow-
ing the procedure and, in general, arterial and central
venous lines are removed.
Conclusions
The emergence of transcatheter valve technology holds
great promise for patients with aortic stenosis who are not
ideal candidates for open surgical repair. It merits empha-
sis that the technology in its present form is not intended
to replace surgical aortic valve replacement in the average
patient. As such, the patients in whom this technology will
be applied will continue to be a challenging population
who will in general be elderly with multiple comorbid
conditions. The convergence of a technically challenging
procedure in a challenging patient subset requires careful
thought and preparation at each time point in the patient’s
hospitalization. This article is meant to outline our system-
atic approach to these patients and hopefully to aid others
in the institution of these programs. There is great hope
that the technology will continue to evolve to make this
novel procedure safer and more widely available in the
near future. Furthermore, the technology in this field isevolving rapidly; the next generation Edwards Sapien XT
is already being used outside the United States and trials in
this country are imminent. It is likely that the devices that
come into clinical use in years to come will have major
iterative improvements from current generations. Even in
its current form, however, this technology holds promise
to treat a large population of symptomatic patients for
whom traditional AVR holds undue risk.
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